Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer, CSIC-University of Salamanca, Spain.
Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca, Spain.
Mol Oncol. 2022 Oct;16(19):3533-3553. doi: 10.1002/1878-0261.13295. Epub 2022 Aug 30.
Mutations in the VAV1 guanine nucleotide exchange factor 1 have been recently found in peripheral T cell lymphoma and nonsmall-cell lung cancer (NSCLC). To understand their pathogenic potential, we generated a gene-edited mouse model that expresses a VAV1 mutant protein that recapitulates the signalling alterations present in the VAV1 mutant subclass most frequently found in tumours. We could not detect any overt tumourigenic process in those mice. However, the concurrent elimination of the Trp53 tumour suppressor gene in them drives T cell lymphomagenesis. This process represents an exacerbation of the normal functions that wild-type VAV1 plays in follicular helper T cells. We also found that, in combination with the Kras oncogene, the VAV1 mutant version favours progression of NSCLC. These data indicate that VAV1 mutations play critical, although highly cell-type-specific, roles in tumourigenesis. They also indicate that such functions are contingent on the mutational landscape of the tumours involved.
最近在周围 T 细胞淋巴瘤和非小细胞肺癌 (NSCLC) 中发现了 VAV1 鸟嘌呤核苷酸交换因子 1 的突变。为了了解它们的致病潜力,我们生成了一种基因编辑小鼠模型,该模型表达了一种 VAV1 突变蛋白,该蛋白再现了在肿瘤中最常发现的 VAV1 突变亚类中存在的信号改变。我们在这些小鼠中没有检测到任何明显的肿瘤发生过程。然而,同时消除它们的 Trp53 肿瘤抑制基因会导致 T 细胞淋巴瘤发生。这个过程代表了野生型 VAV1 在滤泡辅助 T 细胞中的正常功能的加剧。我们还发现,与 Kras 癌基因结合时,VAV1 突变版本有利于 NSCLC 的进展。这些数据表明,VAV1 突变在肿瘤发生中起着关键作用,尽管高度依赖于肿瘤的突变景观。它们还表明,这些功能取决于所涉及肿瘤的突变景观。